This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
and you are
over 18
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).

Provided treatments

  • Drug: Galunisertib 150mg by mouth twice a day
  • Radiation: Stereotactic Body Radiotherapy (SBRT)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02906397. The sponsor of the trial is University of Pennsylvania and it is looking for 15 volunteers for the current phase.
Official trial title:
A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)